JP2007517904A - 置換された複素環化合物及び使用の方法 - Google Patents

Info

Publication number

JP2007517904A

JP2007517904A JP2006549571A JP2006549571A JP2007517904A JP 2007517904 A JP2007517904 A JP 2007517904A JP 2006549571 A JP2006549571 A JP 2006549571A JP 2006549571 A JP2006549571 A JP 2006549571A JP 2007517904 A JP2007517904 A JP 2007517904A

Authority

JP

Japan

Prior art keywords

alkyl

hept

diazabicyclo

phenyl

pyrimidin

Prior art date

2004-01-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims description 49
• 150000001420 substituted heterocyclic compounds Chemical class 0.000 title 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 52
• 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 45
• 201000010099 disease Diseases 0.000 claims abstract description 28
• 230000001404 mediated effect Effects 0.000 claims abstract description 17
• 230000001363 autoimmune Effects 0.000 claims abstract description 16
• 206010061218 Inflammation Diseases 0.000 claims abstract description 14
• 230000001154 acute effect Effects 0.000 claims abstract description 14
• 230000004054 inflammatory process Effects 0.000 claims abstract description 14
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 14
• 238000002054 transplantation Methods 0.000 claims abstract description 13
• 201000004624 Dermatitis Diseases 0.000 claims abstract description 12
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 11
• 102000042846 PKC family Human genes 0.000 claims abstract description 11
• 108091082203 PKC family Proteins 0.000 claims abstract description 11
• 208000010247 contact dermatitis Diseases 0.000 claims abstract description 11
• 208000026935 allergic disease Diseases 0.000 claims abstract description 10
• 208000023328 Basedow disease Diseases 0.000 claims abstract description 9
• 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 9
• 208000006673 asthma Diseases 0.000 claims abstract description 9
• 201000005962 mycosis fungoides Diseases 0.000 claims abstract description 9
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 8
• 206010025135 lupus erythematosus Diseases 0.000 claims abstract description 8
• 230000004083 survival effect Effects 0.000 claims abstract description 8
• 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 7
• 201000004681 Psoriasis Diseases 0.000 claims abstract description 7
• 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 7
• 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 7
• 206010003246 arthritis Diseases 0.000 claims abstract description 7
• 208000037906 ischaemic injury Diseases 0.000 claims abstract description 7
• 230000000302 ischemic effect Effects 0.000 claims abstract description 7
• 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 7
• 208000003950 B-cell lymphoma Diseases 0.000 claims abstract description 6
• 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
• 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
• 206010012442 Dermatitis contact Diseases 0.000 claims abstract description 6
• 208000009329 Graft vs Host Disease Diseases 0.000 claims abstract description 6
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims abstract description 6
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims abstract description 6
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims abstract description 6
• 208000021386 Sjogren Syndrome Diseases 0.000 claims abstract description 6
• 206010042971 T-cell lymphoma Diseases 0.000 claims abstract description 6
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 6
• 239000002246 antineoplastic agent Substances 0.000 claims abstract description 6
• 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 6
• 208000024908 graft versus host disease Diseases 0.000 claims abstract description 6
• 230000009610 hypersensitivity Effects 0.000 claims abstract description 6
• 210000000056 organ Anatomy 0.000 claims abstract description 6
• 208000011580 syndromic disease Diseases 0.000 claims abstract description 6
• 208000026872 Addison Disease Diseases 0.000 claims abstract description 5
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims abstract description 5
• 201000004384 Alopecia Diseases 0.000 claims abstract description 5
• 208000009137 Behcet syndrome Diseases 0.000 claims abstract description 5
• 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 5
• 206010009944 Colon cancer Diseases 0.000 claims abstract description 5
• 208000011231 Crohn disease Diseases 0.000 claims abstract description 5
• 206010018364 Glomerulonephritis Diseases 0.000 claims abstract description 5
• 108010068370 Glutens Proteins 0.000 claims abstract description 5
• 208000015023 Graves' disease Diseases 0.000 claims abstract description 5
• 206010021067 Hypopituitarism Diseases 0.000 claims abstract description 5
• 208000000185 Localized scleroderma Diseases 0.000 claims abstract description 5
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 5
• 208000031845 Pernicious anaemia Diseases 0.000 claims abstract description 5
• 206010037575 Pustular psoriasis Diseases 0.000 claims abstract description 5
• 208000009359 Sezary Syndrome Diseases 0.000 claims abstract description 5
• 201000009594 Systemic Scleroderma Diseases 0.000 claims abstract description 5
• 206010042953 Systemic sclerosis Diseases 0.000 claims abstract description 5
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims abstract description 5
• 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 5
• 208000024780 Urticaria Diseases 0.000 claims abstract description 5
• 206010047642 Vitiligo Diseases 0.000 claims abstract description 5
• 208000028004 allergic respiratory disease Diseases 0.000 claims abstract description 5
• 231100000360 alopecia Toxicity 0.000 claims abstract description 5
• 208000004631 alopecia areata Diseases 0.000 claims abstract description 5
• 208000010668 atopic eczema Diseases 0.000 claims abstract description 5
• 230000001684 chronic effect Effects 0.000 claims abstract description 5
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims abstract description 5
• 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 5
• 201000001981 dermatomyositis Diseases 0.000 claims abstract description 5
• 235000021312 gluten Nutrition 0.000 claims abstract description 5
• 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 5
• 201000005202 lung cancer Diseases 0.000 claims abstract description 5
• 208000020816 lung neoplasm Diseases 0.000 claims abstract description 5
• 201000008482 osteoarthritis Diseases 0.000 claims abstract description 5
• 201000010914 pustulosis of palm and sole Diseases 0.000 claims abstract description 5
• 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims abstract description 5
• 201000004335 respiratory allergy Diseases 0.000 claims abstract description 5
• 230000024664 tolerance induction Effects 0.000 claims abstract description 5
• 230000004614 tumor growth Effects 0.000 claims abstract description 5
• 230000005951 type IV hypersensitivity Effects 0.000 claims abstract description 5
• 208000027930 type IV hypersensitivity disease Diseases 0.000 claims abstract description 5
• 208000003807 Graves Disease Diseases 0.000 claims abstract description 4
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims abstract description 4
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims abstract description 4
• 208000021388 Sezary disease Diseases 0.000 claims abstract description 4
• 208000017983 photosensitivity disease Diseases 0.000 claims abstract description 4
• 208000005057 thyrotoxicosis Diseases 0.000 claims abstract description 4
• 210000004881 tumor cell Anatomy 0.000 claims abstract description 4
• 208000006311 Pyoderma Diseases 0.000 claims abstract description 3
• 206010040400 serum sickness Diseases 0.000 claims abstract description 3
• 238000002689 xenotransplantation Methods 0.000 claims abstract description 3
• 125000000217 alkyl group Chemical group 0.000 claims description 485
• -1 tetrahydronaphthalenyl Chemical group 0.000 claims description 244
• 150000001875 compounds Chemical class 0.000 claims description 187
• 125000001424 substituent group Chemical group 0.000 claims description 104
• 229920006395 saturated elastomer Polymers 0.000 claims description 103
• 125000005843 halogen group Chemical group 0.000 claims description 98
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 88
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 78
• 229910052757 nitrogen Inorganic materials 0.000 claims description 74
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 70
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 69
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 63
• 229910052799 carbon Inorganic materials 0.000 claims description 61
• 125000004043 oxo group Chemical group O=* 0.000 claims description 51
• 125000004432 carbon atom Chemical group C* 0.000 claims description 49
• 229910052739 hydrogen Inorganic materials 0.000 claims description 40
• 229910052760 oxygen Inorganic materials 0.000 claims description 40
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 37
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
• 125000002883 imidazolyl group Chemical group 0.000 claims description 29
• 125000001544 thienyl group Chemical group 0.000 claims description 29
• 241000124008 Mammalia Species 0.000 claims description 28
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 28
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 28
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 28
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 28
• 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 28
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 28
• 125000002541 furyl group Chemical group 0.000 claims description 28
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 28
• 125000001041 indolyl group Chemical group 0.000 claims description 28
• 125000001786 isothiazolyl group Chemical group 0.000 claims description 28
• 125000000842 isoxazolyl group Chemical group 0.000 claims description 28
• 125000002757 morpholinyl group Chemical group 0.000 claims description 28
• 125000002971 oxazolyl group Chemical group 0.000 claims description 28
• 125000004193 piperazinyl group Chemical group 0.000 claims description 28
• 125000003386 piperidinyl group Chemical group 0.000 claims description 28
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 28
• 125000004076 pyridyl group Chemical group 0.000 claims description 28
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 28
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 28
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 28
• 125000000335 thiazolyl group Chemical group 0.000 claims description 28
• 125000001425 triazolyl group Chemical group 0.000 claims description 28
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 27
• 125000001624 naphthyl group Chemical group 0.000 claims description 27
• 229910052717 sulfur Inorganic materials 0.000 claims description 26
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 25
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 25
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 23
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 23
• 125000004306 triazinyl group Chemical group 0.000 claims description 23
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 22
• 125000004429 atom Chemical group 0.000 claims description 20
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 20
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 20
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 20
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 20
• 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 19
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 17
• 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 16
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 15
• 125000004434 sulfur atom Chemical group 0.000 claims description 14
• 125000002619 bicyclic group Chemical group 0.000 claims description 13
• 208000035475 disorder Diseases 0.000 claims description 13
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
• 150000003839 salts Chemical class 0.000 claims description 12
• 230000006044 T cell activation Effects 0.000 claims description 11
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
• NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 claims description 9
• FQJRZOYTUCCBQR-UHFFFAOYSA-N tert-butyl 2-methylheptanoate Chemical compound CCCCCC(C)C(=O)OC(C)(C)C FQJRZOYTUCCBQR-UHFFFAOYSA-N 0.000 claims description 9
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 208000032839 leukemia Diseases 0.000 claims description 8
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
• 206010022489 Insulin Resistance Diseases 0.000 claims description 7
• 229910052794 bromium Inorganic materials 0.000 claims description 7
• 229910052801 chlorine Inorganic materials 0.000 claims description 7
• 229910052731 fluorine Inorganic materials 0.000 claims description 7
• 229910052740 iodine Inorganic materials 0.000 claims description 7
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
• 201000008937 atopic dermatitis Diseases 0.000 claims description 6
• 201000011510 cancer Diseases 0.000 claims description 6
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 5
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
• 125000003047 N-acetyl group Chemical group 0.000 claims description 5
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
• HUSCFUXDGASTLI-YDIPPGQESA-N 4-[5-[(1s,4s)-5-(2-phenoxypropyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CC(C)OC=2C=CC=CC=2)[H])=CC=CC=C1 HUSCFUXDGASTLI-YDIPPGQESA-N 0.000 claims description 4
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 4
• 208000008732 thymoma Diseases 0.000 claims description 4
• RQGMJYSQCBDCMZ-VJBMBRPKSA-N 4-[4-[(1s,4s)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinazolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)CC)[H])=CC=CC=C1 RQGMJYSQCBDCMZ-VJBMBRPKSA-N 0.000 claims description 3
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• GKTBKKVWPNGMFG-NYVOZVTQSA-N n-[(1s)-1-phenylethyl]-4-[2-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=CN=C(N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 GKTBKKVWPNGMFG-NYVOZVTQSA-N 0.000 claims description 3
• LWQDICDZDSPXPQ-OYDLWJJNSA-N n-[(1s)-1-phenylethyl]-4-[4-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]quinazolin-2-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 LWQDICDZDSPXPQ-OYDLWJJNSA-N 0.000 claims description 3
• SIIQBMIBASOKOD-ICSRJNTNSA-N n-benzyl-4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-6-fluoroindazol-1-yl]pyridin-2-amine Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(C1=CC=C(F)C=C11)=NN1C(C=1)=CC=NC=1NCC1=CC=CC=C1 SIIQBMIBASOKOD-ICSRJNTNSA-N 0.000 claims description 3
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
• 208000023504 respiratory system disease Diseases 0.000 claims description 3
• OLFFOWYNQJKLDU-SNRMKQJTSA-N 2-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-3-methyl-6-[2-[[(1s)-1-phenylethyl]amino]pyridin-4-yl]pyrimidin-4-one Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N(C(=O)C=2)C)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 OLFFOWYNQJKLDU-SNRMKQJTSA-N 0.000 claims description 2
• MUSPLTOFMXRFOE-NDXORKPFSA-N 4-[2-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]pyridin-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(N=CC=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 MUSPLTOFMXRFOE-NDXORKPFSA-N 0.000 claims description 2
• BZLNQHVXJPCZCT-NYVOZVTQSA-N 4-[2-methylsulfanyl-6-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(N=C(SC)N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 BZLNQHVXJPCZCT-NYVOZVTQSA-N 0.000 claims description 2
• PKWBFXMNHSZDTB-LNLFQRSKSA-N 4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]indazol-1-yl]-n-[(1s)-1-(2-fluorophenyl)ethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)N2N=C(C3=CC=CC=C32)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1F PKWBFXMNHSZDTB-LNLFQRSKSA-N 0.000 claims description 2
• TWYYQCKDAVLTKR-CUWPLCDZSA-N 4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]indazol-1-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)N2N=C(C3=CC=CC=C32)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 TWYYQCKDAVLTKR-CUWPLCDZSA-N 0.000 claims description 2
• VZMQHTHDLXOOET-YYWHXJBOSA-N 4-[4-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinazolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(C3=CC=CC=C3N=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 VZMQHTHDLXOOET-YYWHXJBOSA-N 0.000 claims description 2
• UXAGYDYQHFDNBY-NYVOZVTQSA-N 4-[4-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C3=CC=CC=C3N=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 UXAGYDYQHFDNBY-NYVOZVTQSA-N 0.000 claims description 2
• ZABHCFAMEITAHK-OYDLWJJNSA-N 4-[4-[(1s,4s)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)CC)[H])=CC=CC=C1 ZABHCFAMEITAHK-OYDLWJJNSA-N 0.000 claims description 2
• FDAUXZFXTPDSRM-NYVOZVTQSA-N 4-[4-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinazolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)C)[H])=CC=CC=C1 FDAUXZFXTPDSRM-NYVOZVTQSA-N 0.000 claims description 2
• RVQIRCOGFQIAJJ-VJBMBRPKSA-N 4-[4-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)C)[H])=CC=CC=C1 RVQIRCOGFQIAJJ-VJBMBRPKSA-N 0.000 claims description 2
• YMPJQANVEGWILT-YYWHXJBOSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-n-[(1s)-1-naphthalen-1-ylethyl]pyridin-2-amine Chemical compound C1=CC=C2C([C@H](C)NC=3N=CC=C(C=3)C=3N=C(N4N=CN=C4C=3)N3C[C@]4(NC[C@]3([H])C4)[H])=CC=CC2=C1 YMPJQANVEGWILT-YYWHXJBOSA-N 0.000 claims description 2
• JKVGSSMZDIFZSF-UXPWSPDFSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1r)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 JKVGSSMZDIFZSF-UXPWSPDFSA-N 0.000 claims description 2
• XIXXFELFCFBDOU-OLKLTNODSA-N 4-[5-[(1s,4s)-2-butan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)CC)[H])=CC=CC=C1 XIXXFELFCFBDOU-OLKLTNODSA-N 0.000 claims description 2
• BRIYHAYUDAJLJV-VJBMBRPKSA-N 4-[5-[(1s,4s)-2-tert-butyl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@@]2(C3)[H])C(C)(C)C)[H])=CC=CC=C1 BRIYHAYUDAJLJV-VJBMBRPKSA-N 0.000 claims description 2
• NBMSKMMNDPHSAZ-DKICCIFJSA-N 4-[5-[(1s,4s)-3-methyl-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@@]3(C[C@@]2([H])C(C)N3C(C)C)[H])=CC=CC=C1 NBMSKMMNDPHSAZ-DKICCIFJSA-N 0.000 claims description 2
• XHQNKBJBTQDUFF-ZVJDSTMCSA-N 4-[5-[(1s,4s)-5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]-3h-pyridin-4-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)CC(F)F)[H])N2C(N1C=CN=C1C=1)=NC=1C1(N[C@@H](C)C=2C=CC=CC=2)CC=NC=C1 XHQNKBJBTQDUFF-ZVJDSTMCSA-N 0.000 claims description 2
• GUHQBASITAZOSX-OYDLWJJNSA-N 4-[5-[(1s,4s)-5-(2-methylpropyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CC(C)C)[H])=CC=CC=C1 GUHQBASITAZOSX-OYDLWJJNSA-N 0.000 claims description 2
• BBLOJEWCGIQPDH-YGPDHOBYSA-N 4-[5-[(1s,4s)-5-(2-phenoxyethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CCOC=2C=CC=CC=2)[H])=CC=CC=C1 BBLOJEWCGIQPDH-YGPDHOBYSA-N 0.000 claims description 2
• QGKQXIRIUYZUDY-CAVYSCNFSA-N 4-[5-[(1s,4s)-5-benzyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CC=2C=CC=CC=2)[H])=CC=CC=C1 QGKQXIRIUYZUDY-CAVYSCNFSA-N 0.000 claims description 2
• XKSYHHVIDRYCNU-OYDLWJJNSA-N 4-[5-[(1s,4s)-5-butyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CCCC)[H])=CC=CC=C1 XKSYHHVIDRYCNU-OYDLWJJNSA-N 0.000 claims description 2
• UALKGXILIOUUGQ-OPXMRZJTSA-N 4-[5-[(1s,4s)-5-cyclopentyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C2CCCC2)[H])=CC=CC=C1 UALKGXILIOUUGQ-OPXMRZJTSA-N 0.000 claims description 2
• YWLVWOCNSRYDHO-YYWHXJBOSA-N 4-[5-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C)[H])=CC=CC=C1 YWLVWOCNSRYDHO-YYWHXJBOSA-N 0.000 claims description 2
• MTFKWAAUPVJALN-SNRMKQJTSA-N 4-[6-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-2-methylsulfanylpyrimidin-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(N=C(SC)N=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 MTFKWAAUPVJALN-SNRMKQJTSA-N 0.000 claims description 2
• 230000001413 cellular effect Effects 0.000 claims description 2
• CRZSXSCVAOQWRE-OYDLWJJNSA-N n-(2,2-dimethoxyethyl)-6-[2-[[(1s)-1-phenylethyl]amino]pyridin-4-yl]-2-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(NCC(OC)OC)N=C(N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 CRZSXSCVAOQWRE-OYDLWJJNSA-N 0.000 claims description 2
• ATQRNTSLYSZOSI-OIBXWCBGSA-N n-[(1r)-1-phenylethyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 ATQRNTSLYSZOSI-OIBXWCBGSA-N 0.000 claims description 2
• AWAZGPBUVSVEEK-OYDLWJJNSA-N n-[(1s)-1-naphthalen-1-ylethyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1=CC=C2C([C@H](C)NC=3N=CC=C(C=3)C=3N=C(N4N=CN=C4C=3)N3C[C@]4(N(C[C@]3([H])C4)C(C)C)[H])=CC=CC2=C1 AWAZGPBUVSVEEK-OYDLWJJNSA-N 0.000 claims description 2
• PYLNCHYZWPUCNK-TUSQITKMSA-N n-[(1s)-1-phenylethyl]-4-[4-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]quinolin-2-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C3=CC=CC=C3N=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 PYLNCHYZWPUCNK-TUSQITKMSA-N 0.000 claims description 2
• FQVUVUVONWTCJN-VJBMBRPKSA-N n-[(1s)-1-phenylethyl]-4-[5-[(1s,4s)-5-propyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CCC)[H])=CC=CC=C1 FQVUVUVONWTCJN-VJBMBRPKSA-N 0.000 claims description 2
• 238000001959 radiotherapy Methods 0.000 claims description 2
• 238000006467 substitution reaction Methods 0.000 claims description 2
• VBRRTWCBLMRCLU-OYDLWJJNSA-N tert-butyl (1s,4s)-5-[1-[2-[[(1s)-1-phenylethyl]amino]pyridin-4-yl]indazol-3-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)N2N=C(C3=CC=CC=C32)N2C[C@]3(N(C[C@]2([H])C3)C(=O)OC(C)(C)C)[H])=CC=CC=C1 VBRRTWCBLMRCLU-OYDLWJJNSA-N 0.000 claims description 2
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
• LYLWBIPQXXROQN-UHFFFAOYSA-N CC(C)N(CC1C2)C2CN1C1=NC(C2=CC=CN=C2NCC2=CC=CC3=CC=CC=C23)=CC2=NC=CN12 Chemical compound CC(C)N(CC1C2)C2CN1C1=NC(C2=CC=CN=C2NCC2=CC=CC3=CC=CC=C23)=CC2=NC=CN12 LYLWBIPQXXROQN-UHFFFAOYSA-N 0.000 claims 1
• 206010030113 Oedema Diseases 0.000 claims 1
• 208000020424 Polyglandular disease Diseases 0.000 claims 1
• 230000003213 activating effect Effects 0.000 claims 1
• DTIGGPHKRSURDR-DQEYMECFSA-N n-(naphthalen-1-ylmethyl)-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1=CC=C2C(CNC=3N=CC=C(C=3)C=3N=C(N4C=CN=C4C=3)N3C[C@]4(N(C[C@]3([H])C4)C(C)C)[H])=CC=CC2=C1 DTIGGPHKRSURDR-DQEYMECFSA-N 0.000 claims 1
• CHCSYRDEXKBZGG-YYWHXJBOSA-N n-[(1s)-1-phenylethyl]-4-[2-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]-1,3-thiazol-4-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(SC=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 CHCSYRDEXKBZGG-YYWHXJBOSA-N 0.000 claims 1
• CZSYKLHLDRGUJW-OYDLWJJNSA-N n-[(1s)-1-phenylethyl]-4-[3-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]indazol-1-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)N2N=C(C3=CC=CC=C32)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 CZSYKLHLDRGUJW-OYDLWJJNSA-N 0.000 claims 1
• DMVHEESFRSZGIP-OCPXOFMESA-N n-[(1s)-1-phenylethyl]-4-[5-[(1s,4s)-2-(1,1,1-trifluoropropan-2-yl)-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C(F)(F)F)[H])=CC=CC=C1 DMVHEESFRSZGIP-OCPXOFMESA-N 0.000 claims 1
• AIHQJENGTXVKMP-NYVOZVTQSA-N n-[(1s)-1-phenylethyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3N=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 AIHQJENGTXVKMP-NYVOZVTQSA-N 0.000 claims 1
• TZRHQHMCEFZZPQ-SFTDATJTSA-N n-[(2-fluorophenyl)methyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C(C)C)[H])N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NCC1=CC=CC=C1F TZRHQHMCEFZZPQ-SFTDATJTSA-N 0.000 claims 1
• RSWBCBOTSKKQOL-VXKWHMMOSA-N n-benzyl-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C(C)C)[H])N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NCC1=CC=CC=C1 RSWBCBOTSKKQOL-VXKWHMMOSA-N 0.000 claims 1
• 125000000547 substituted alkyl group Chemical group 0.000 claims 1
• 238000011282 treatment Methods 0.000 abstract description 23
• 208000000389 T-cell leukemia Diseases 0.000 abstract description 5
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 abstract description 4
• 230000001225 therapeutic effect Effects 0.000 abstract description 4
• 230000005784 autoimmunity Effects 0.000 abstract description 2
• 210000000481 breast Anatomy 0.000 abstract description 2
• 230000000241 respiratory effect Effects 0.000 abstract description 2
• 208000003200 Adenoma Diseases 0.000 abstract 1
• 206010003645 Atopy Diseases 0.000 abstract 1
• 239000000203 mixture Substances 0.000 description 198
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 170
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 129
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
• 239000007787 solid Substances 0.000 description 79
• 239000011734 sodium Substances 0.000 description 77
• 238000000746 purification Methods 0.000 description 71
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 60
• 238000003818 flash chromatography Methods 0.000 description 49
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
• 239000007858 starting material Substances 0.000 description 42
• 238000006243 chemical reaction Methods 0.000 description 39
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
• 239000011541 reaction mixture Substances 0.000 description 34
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
• 235000019439 ethyl acetate Nutrition 0.000 description 30
• 239000000243 solution Substances 0.000 description 30
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
• 210000004027 cell Anatomy 0.000 description 22
• MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 20
• 230000000694 effects Effects 0.000 description 20
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 20
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
• 239000003112 inhibitor Substances 0.000 description 18
• 239000012044 organic layer Substances 0.000 description 18
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
• 239000012267 brine Substances 0.000 description 17
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
• 238000004587 chromatography analysis Methods 0.000 description 16
• 239000012043 crude product Substances 0.000 description 16
• 239000003814 drug Substances 0.000 description 16
• 238000003556 assay Methods 0.000 description 15
• 238000004519 manufacturing process Methods 0.000 description 15
• 102000000588 Interleukin-2 Human genes 0.000 description 13
• 108010002350 Interleukin-2 Proteins 0.000 description 13
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
• 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 12
• 108090000315 Protein Kinase C Proteins 0.000 description 12
• 102000003923 Protein Kinase C Human genes 0.000 description 12
• 102100024924 Protein kinase C alpha type Human genes 0.000 description 12
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
• 235000019441 ethanol Nutrition 0.000 description 11
• 238000004128 high performance liquid chromatography Methods 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 239000002904 solvent Substances 0.000 description 11
• 238000003756 stirring Methods 0.000 description 11
• RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 10
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 10
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 10
• 108091008874 T cell receptors Proteins 0.000 description 10
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 10
• 150000001412 amines Chemical class 0.000 description 10
• 239000007788 liquid Substances 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 230000005587 bubbling Effects 0.000 description 9
• 239000010410 layer Substances 0.000 description 9
• UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 description 9
• 108010044467 Isoenzymes Proteins 0.000 description 8
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• IGRLNCOFYMWKBU-UHFFFAOYSA-N ethyl 2-chloropyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(Cl)=C1 IGRLNCOFYMWKBU-UHFFFAOYSA-N 0.000 description 8
• VQESHCXOMUBUOE-UHFFFAOYSA-N ethyl 3-(2-chloropyridin-4-yl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=NC(Cl)=C1 VQESHCXOMUBUOE-UHFFFAOYSA-N 0.000 description 8
• 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 8
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 8
• 229940002612 prodrug Drugs 0.000 description 8
• 239000000651 prodrug Substances 0.000 description 8
• 125000006239 protecting group Chemical group 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
• 230000004913 activation Effects 0.000 description 7
• 125000003710 aryl alkyl group Chemical group 0.000 description 7
• 210000003630 histaminocyte Anatomy 0.000 description 7
• WYAKPHAFBORCJU-UHFFFAOYSA-N 4-chloro-6-(2-chloropyridin-4-yl)-2-methylsulfanylpyrimidine Chemical compound CSC1=NC(Cl)=CC(C=2C=C(Cl)N=CC=2)=N1 WYAKPHAFBORCJU-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 102000004127 Cytokines Human genes 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 6
• 108091000080 Phosphotransferase Proteins 0.000 description 6
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 229910002091 carbon monoxide Inorganic materials 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 6
• 102000020233 phosphotransferase Human genes 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 108090000623 proteins and genes Proteins 0.000 description 6
• 230000028327 secretion Effects 0.000 description 6
• QBVIAVCHWMDZEE-UHFFFAOYSA-N 6-(2-chloropyridin-4-yl)-n-(2,2-dimethoxyethyl)-2-methylsulfanylpyrimidin-4-amine Chemical compound CSC1=NC(NCC(OC)OC)=CC(C=2C=C(Cl)N=CC=2)=N1 QBVIAVCHWMDZEE-UHFFFAOYSA-N 0.000 description 5
• GRIOWTNZRKWBRR-UHFFFAOYSA-N 7-(2-chloropyridin-4-yl)-6h-imidazo[1,2-c]pyrimidin-5-one Chemical compound C=1C2=NC=CN2C(O)=NC=1C1=CC=NC(Cl)=C1 GRIOWTNZRKWBRR-UHFFFAOYSA-N 0.000 description 5
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 5
• 102100024923 Protein kinase C beta type Human genes 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 125000003118 aryl group Chemical group 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 238000001816 cooling Methods 0.000 description 5
• 201000011190 diabetic macular edema Diseases 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 230000036457 multidrug resistance Effects 0.000 description 5
• 210000000440 neutrophil Anatomy 0.000 description 5
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 239000002244 precipitate Substances 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 238000010992 reflux Methods 0.000 description 5
• ZCBUQCWBWNUWSU-SFHVURJKSA-N ruboxistaurin Chemical compound O=C1NC(=O)C2=C1C(C1=CC=CC=C11)=CN1CCO[C@H](CN(C)C)CCN1C3=CC=CC=C3C2=C1 ZCBUQCWBWNUWSU-SFHVURJKSA-N 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 4
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
• XVXJVHGOGUUFCV-UHFFFAOYSA-N 5-chloro-7-(2-chloropyridin-4-yl)imidazo[1,2-c]pyrimidine Chemical compound C1=NC(Cl)=CC(C=2N=C(Cl)N3C=CN=C3C=2)=C1 XVXJVHGOGUUFCV-UHFFFAOYSA-N 0.000 description 4
• RHICYBDTZDMHOL-UHFFFAOYSA-N 6-(2-chloropyridin-4-yl)-2-methylsulfanyl-1h-pyrimidin-4-one Chemical compound O=C1NC(SC)=NC(C=2C=C(Cl)N=CC=2)=C1 RHICYBDTZDMHOL-UHFFFAOYSA-N 0.000 description 4
• 0 CC(N=C(C)N1*)=C(*)C1=O Chemical compound CC(N=C(C)N1*)=C(*)C1=O 0.000 description 4
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 239000000975 dye Substances 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 230000014509 gene expression Effects 0.000 description 4
• 125000000623 heterocyclic group Chemical group 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• DRCWDHQXGIVRKV-UHFFFAOYSA-N tert-butyl 5-[7-(2-chloropyridin-4-yl)imidazo[1,2-c]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2CC1CN2C(N1C=CN=C1C=1)=NC=1C1=CC=NC(Cl)=C1 DRCWDHQXGIVRKV-UHFFFAOYSA-N 0.000 description 4
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 238000004809 thin layer chromatography Methods 0.000 description 4
• 229940104230 thymidine Drugs 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• QXCOHSRHFCHCHN-UHFFFAOYSA-N 2-chloropyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(Cl)=C1 QXCOHSRHFCHCHN-UHFFFAOYSA-N 0.000 description 3
• WBUDEGTYTUJGIV-ROUUACIJSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(2-fluorophenyl)methyl]pyridin-2-amine Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NCC1=CC=CC=C1F WBUDEGTYTUJGIV-ROUUACIJSA-N 0.000 description 3
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 125000002252 acyl group Chemical group 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000007327 hydrogenolysis reaction Methods 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 239000005457 ice water Substances 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 239000003701 inert diluent Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000009696 proliferative response Effects 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 229950000261 ruboxistaurin Drugs 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 210000002027 skeletal muscle Anatomy 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
• UXAWXZDXVOYLII-JAMMHHFISA-N tert-butyl (4s)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2CN[C@]1([H])CN2C(=O)OC(C)(C)C UXAWXZDXVOYLII-JAMMHHFISA-N 0.000 description 3
• MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• QGPMEPLSFKEQBA-MTICXXPYSA-N (1s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptane;hydrochloride Chemical compound Cl.C1NC2CN(C(C)C)[C@@]1([H])C2 QGPMEPLSFKEQBA-MTICXXPYSA-N 0.000 description 2
• LRFWYBZWRQWZIM-UHFFFAOYSA-N (2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC=C1F LRFWYBZWRQWZIM-UHFFFAOYSA-N 0.000 description 2
• ZJCGPQZERFBGSM-UHFFFAOYSA-N 1-(2-chloropyridin-4-yl)ethanone Chemical compound CC(=O)C1=CC=NC(Cl)=C1 ZJCGPQZERFBGSM-UHFFFAOYSA-N 0.000 description 2
• MNMDZSAWTQOEHX-BDAKNGLRSA-N 1-o-tert-butyl 2-o-ethyl (2s,4r)-4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound CCOC(=O)[C@@H]1C[C@@H](O)CN1C(=O)OC(C)(C)C MNMDZSAWTQOEHX-BDAKNGLRSA-N 0.000 description 2
• OEGMTFRNUKJZNO-UHFFFAOYSA-N 2-(2-chloropyridin-4-yl)-1h-quinolin-4-one Chemical compound N=1C2=CC=CC=C2C(O)=CC=1C1=CC=NC(Cl)=C1 OEGMTFRNUKJZNO-UHFFFAOYSA-N 0.000 description 2
• PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• ACYHAAZAFBDUHT-UHFFFAOYSA-N 2-[[6-(2-chloropyridin-4-yl)-2-methylsulfanylpyrimidin-4-yl]amino]ethanol Chemical compound CSC1=NC(NCCO)=CC(C=2C=C(Cl)N=CC=2)=N1 ACYHAAZAFBDUHT-UHFFFAOYSA-N 0.000 description 2
• RRKPMLZRLKTDQV-UHFFFAOYSA-N 2-bromo-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1Br RRKPMLZRLKTDQV-UHFFFAOYSA-N 0.000 description 2
• XRXMNWGCKISMOH-UHFFFAOYSA-N 2-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Br XRXMNWGCKISMOH-UHFFFAOYSA-N 0.000 description 2
• GHISNTVCGGIMRA-UHFFFAOYSA-N 2-chloro-1-(2-chloropyridin-4-yl)ethanone Chemical compound ClCC(=O)C1=CC=NC(Cl)=C1 GHISNTVCGGIMRA-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• INSOGOCJEZANTA-UHFFFAOYSA-N 4-(2-chloropyridin-4-yl)-6-methyl-2-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=NC(C)=CC(C=2C=C(Cl)N=CC=2)=N1 INSOGOCJEZANTA-UHFFFAOYSA-N 0.000 description 2
• WXCARTUZUBOCGO-UHFFFAOYSA-N 4-chloro-2-(2-chloropyridin-4-yl)quinazoline Chemical compound C1=NC(Cl)=CC(C=2N=C3C=CC=CC3=C(Cl)N=2)=C1 WXCARTUZUBOCGO-UHFFFAOYSA-N 0.000 description 2
• YWTFFBXMIBPNTH-GJZGRUSLSA-N 5-[(1s,4s)-2-tert-butyl-2,5-diazabicyclo[2.2.1]heptan-5-yl]-7-(2-chloropyridin-4-yl)imidazo[1,2-c]pyrimidine Chemical compound C([C@]1(N(C[C@@]2(C1)[H])C(C)(C)C)[H])N2C(N1C=CN=C1C=1)=NC=1C1=CC=NC(Cl)=C1 YWTFFBXMIBPNTH-GJZGRUSLSA-N 0.000 description 2
• CXSLWWNSXUZQBN-UHFFFAOYSA-N 6-(2-chloropyridin-4-yl)-3-methyl-2-methylsulfanylpyrimidin-4-one Chemical compound O=C1N(C)C(SC)=NC(C=2C=C(Cl)N=CC=2)=C1 CXSLWWNSXUZQBN-UHFFFAOYSA-N 0.000 description 2
• MDDHLLIVOCWBHU-UHFFFAOYSA-N 6-(2-chloropyridin-4-yl)-n-(2,2-dimethoxyethyl)-2-(2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl)pyrimidin-4-amine Chemical compound N=1C(N2C3CC(N(C3)C(C)C)C2)=NC(NCC(OC)OC)=CC=1C1=CC=NC(Cl)=C1 MDDHLLIVOCWBHU-UHFFFAOYSA-N 0.000 description 2
• ARMTWGOJFFCUKB-UHFFFAOYSA-N 6-(2-chloropyridin-4-yl)-n-(2,2-dimethoxyethyl)-2-methylsulfinylpyrimidin-4-amine Chemical compound CS(=O)C1=NC(NCC(OC)OC)=CC(C=2C=C(Cl)N=CC=2)=N1 ARMTWGOJFFCUKB-UHFFFAOYSA-N 0.000 description 2
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• PMCOWOCKUQWYRL-UHFFFAOYSA-N Cc1nc(C)ncc1 Chemical compound Cc1nc(C)ncc1 PMCOWOCKUQWYRL-UHFFFAOYSA-N 0.000 description 2
• QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 208000001204 Hashimoto Disease Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 102000004890 Interleukin-8 Human genes 0.000 description 2
• 108090001007 Interleukin-8 Proteins 0.000 description 2
• AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 230000006052 T cell proliferation Effects 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 235000011054 acetic acid Nutrition 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 210000003651 basophil Anatomy 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
• 125000005605 benzo group Chemical group 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 239000003560 cancer drug Substances 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 238000001516 cell proliferation assay Methods 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 239000012230 colorless oil Substances 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000012897 dilution medium Substances 0.000 description 2
• USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• HHXSZDXMSRXWJV-IBTYICNHSA-N ethyl (2s,4r)-4-hydroxypyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)[C@@H]1C[C@@H](O)CN1 HHXSZDXMSRXWJV-IBTYICNHSA-N 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 239000003365 glass fiber Substances 0.000 description 2
• 229940074045 glyceryl distearate Drugs 0.000 description 2
• 229940075507 glyceryl monostearate Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 229910052736 halogen Inorganic materials 0.000 description 2
• 150000002367 halogens Chemical class 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000004073 interleukin-2 production Effects 0.000 description 2
• 229940100601 interleukin-6 Drugs 0.000 description 2
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
• 229940096397 interleukin-8 Drugs 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• CZSYKLHLDRGUJW-BMTNDILFSA-N n-(1-phenylethyl)-4-[3-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]indazol-1-yl]pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C(C)C)[H])N2C(C1=CC=CC=C11)=NN1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 CZSYKLHLDRGUJW-BMTNDILFSA-N 0.000 description 2
• PYLNCHYZWPUCNK-MHKYCTGGSA-N n-(1-phenylethyl)-4-[4-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]quinolin-2-yl]pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C(C)C)[H])N2C(C1=CC=CC=C1N=1)=CC=1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 PYLNCHYZWPUCNK-MHKYCTGGSA-N 0.000 description 2
• XZSCQXCGJYANCB-UHFFFAOYSA-N n-[2-[tert-butyl(diphenyl)silyl]oxyethyl]-6-(2-chloropyridin-4-yl)-2-methylsulfinylpyrimidin-4-amine Chemical compound C=1C(C=2C=C(Cl)N=CC=2)=NC(S(=O)C)=NC=1NCCO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 XZSCQXCGJYANCB-UHFFFAOYSA-N 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000012038 nucleophile Substances 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 208000009954 pyoderma gangrenosum Diseases 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000011808 rodent model Methods 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 238000006884 silylation reaction Methods 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• LIZVWJJFLOXLII-ZUEZHPSSSA-N tert-butyl (1r)-5-[7-[2-(1-phenylethylamino)pyridin-4-yl]imidazo[1,2-c]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C([C@@](N(C1)C(=O)OC(C)(C)C)(C2)[H])C1N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 LIZVWJJFLOXLII-ZUEZHPSSSA-N 0.000 description 2
• UXAWXZDXVOYLII-YUMQZZPRSA-N tert-butyl (1s,4s)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1[C@@H]2N(C(=O)OC(C)(C)C)C[C@H]1NC2 UXAWXZDXVOYLII-YUMQZZPRSA-N 0.000 description 2
• NJBRZZCPRDXTKN-GJZUVCINSA-N tert-butyl (2S,4R)-4-[tert-butyl(diphenyl)silyl]-2-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@](C[C@H](C1)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)(CO)O NJBRZZCPRDXTKN-GJZUVCINSA-N 0.000 description 2
• QUSBMWKWKFSNBI-UHFFFAOYSA-N tert-butyl 5-[2-(2-chloropyridin-4-yl)quinolin-4-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2CC1CN2C(C1=CC=CC=C1N=1)=CC=1C1=CC=NC(Cl)=C1 QUSBMWKWKFSNBI-UHFFFAOYSA-N 0.000 description 2
• LOVMVLNCUDYXSP-UHFFFAOYSA-N tert-butyl 5-[2-methylsulfanyl-6-[2-(1-phenylethylamino)pyridin-4-yl]pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound N=1C(SC)=NC(N2C3CC(N(C3)C(=O)OC(C)(C)C)C2)=CC=1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 LOVMVLNCUDYXSP-UHFFFAOYSA-N 0.000 description 2
• FYPVOSYRGWUIJH-UHFFFAOYSA-N tert-butyl 5-[4-(2-chloropyridin-4-yl)-6-methylpyrimidin-2-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound N=1C(N2C3CC(N(C3)C(=O)OC(C)(C)C)C2)=NC(C)=CC=1C1=CC=NC(Cl)=C1 FYPVOSYRGWUIJH-UHFFFAOYSA-N 0.000 description 2
• LHAGITCOMOVCCR-UHFFFAOYSA-N tert-butyl 5-[6-(2-chloropyridin-4-yl)-2-methylsulfanylpyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound N=1C(SC)=NC(N2C3CC(N(C3)C(=O)OC(C)(C)C)C2)=CC=1C1=CC=NC(Cl)=C1 LHAGITCOMOVCCR-UHFFFAOYSA-N 0.000 description 2
• LIZVWJJFLOXLII-UHFFFAOYSA-N tert-butyl 5-[7-[2-(1-phenylethylamino)pyridin-4-yl]imidazo[1,2-c]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C=1C(C=2N=C(N3C=CN=C3C=2)N2C3CC(N(C3)C(=O)OC(C)(C)C)C2)=CC=NC=1NC(C)C1=CC=CC=C1 LIZVWJJFLOXLII-UHFFFAOYSA-N 0.000 description 2
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
• KVTRUBZAMRIDHX-WHFBIAKZSA-N (1s,4s)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid Chemical compound C1N(C(O)=O)[C@]2([H])CN[C@@]1([H])C2 KVTRUBZAMRIDHX-WHFBIAKZSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• LLNAMUJRIZIXHF-CLFYSBASSA-N (z)-2-methyl-3-phenylprop-2-en-1-ol Chemical compound OCC(/C)=C\C1=CC=CC=C1 LLNAMUJRIZIXHF-CLFYSBASSA-N 0.000 description 1
• FHUDAMLDXFJHJE-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-one Chemical compound CC(=O)C(F)(F)F FHUDAMLDXFJHJE-UHFFFAOYSA-N 0.000 description 1
• 125000004901 1,2-dimethylpropylamino group Chemical group CC(C(C)C)N* 0.000 description 1
• DIWHJJUFVGEXGS-UHFFFAOYSA-N 1-(2-fluorophenyl)ethanamine Chemical compound CC(N)C1=CC=CC=C1F DIWHJJUFVGEXGS-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• MNMDZSAWTQOEHX-UHFFFAOYSA-N 1-o-tert-butyl 2-o-ethyl 4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound CCOC(=O)C1CC(O)CN1C(=O)OC(C)(C)C MNMDZSAWTQOEHX-UHFFFAOYSA-N 0.000 description 1
• RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
• 150000007545 14-membered macrocycles Chemical class 0.000 description 1
• UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
• XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 1
• NKULBUOBGILEAR-UHFFFAOYSA-N 2,2-difluoroethyl trifluoromethanesulfonate Chemical compound FC(F)COS(=O)(=O)C(F)(F)F NKULBUOBGILEAR-UHFFFAOYSA-N 0.000 description 1
• QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
• TUQSVSYUEBNNKQ-UHFFFAOYSA-N 2,4-dichloroquinazoline Chemical compound C1=CC=CC2=NC(Cl)=NC(Cl)=C21 TUQSVSYUEBNNKQ-UHFFFAOYSA-N 0.000 description 1
• UKHJNJFJCGBKSF-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.1]heptane Chemical compound C1NC2CNC1C2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 description 1
• OLFFOWYNQJKLDU-UHFFFAOYSA-N 2-(2,5-diazabicyclo[2.2.1]heptan-2-yl)-3-methyl-6-[2-(1-phenylethylamino)pyridin-4-yl]pyrimidin-4-one Chemical compound C=1C(C=2N=C(N(C)C(=O)C=2)N2C3CC(NC3)C2)=CC=NC=1NC(C)C1=CC=CC=C1 OLFFOWYNQJKLDU-UHFFFAOYSA-N 0.000 description 1
• WKRMNPJNOYZDEA-UHFFFAOYSA-N 2-(2-chloropyridin-4-yl)-1h-quinazolin-4-one Chemical compound C1=NC(Cl)=CC(C=2NC(=O)C3=CC=CC=C3N=2)=C1 WKRMNPJNOYZDEA-UHFFFAOYSA-N 0.000 description 1
• ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
• AXZRUTPBQMAWLP-UHFFFAOYSA-N 2-bromo-4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C(Br)=C1 AXZRUTPBQMAWLP-UHFFFAOYSA-N 0.000 description 1
• JJFOBACUIRKUPN-UHFFFAOYSA-N 2-bromoethoxybenzene Chemical compound BrCCOC1=CC=CC=C1 JJFOBACUIRKUPN-UHFFFAOYSA-N 0.000 description 1
• UUEQDBHKMOFLDP-UHFFFAOYSA-N 2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC(Cl)=C1 UUEQDBHKMOFLDP-UHFFFAOYSA-N 0.000 description 1
• YZJSARUCMYJHNV-UHFFFAOYSA-N 2-dimethylsilylethyl(dimethyl)silane Chemical compound C[SiH](C)CC[SiH](C)C YZJSARUCMYJHNV-UHFFFAOYSA-N 0.000 description 1
• NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
• FUMTXFNRSOTREL-UHFFFAOYSA-N 2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptane Chemical compound C1C2N(C(C)C)CC1NC2 FUMTXFNRSOTREL-UHFFFAOYSA-N 0.000 description 1
• WJKMUGYQMMXILX-UHFFFAOYSA-N 2-trimethylsilylacetonitrile Chemical compound C[Si](C)(C)CC#N WJKMUGYQMMXILX-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• NIDWUZTTXGJFNN-UHFFFAOYSA-N 3-bromopropoxybenzene Chemical compound BrCCCOC1=CC=CC=C1 NIDWUZTTXGJFNN-UHFFFAOYSA-N 0.000 description 1
• JFSOTTKKBLOHTK-UHFFFAOYSA-N 3-chloro-1-(2-chloropyridin-4-yl)indazole Chemical compound C12=CC=CC=C2C(Cl)=NN1C1=CC=NC(Cl)=C1 JFSOTTKKBLOHTK-UHFFFAOYSA-N 0.000 description 1
• QPHAGNNWDZSKJH-UHFFFAOYSA-N 3-chloro-2h-indazole Chemical compound C1=CC=CC2=C(Cl)NN=C21 QPHAGNNWDZSKJH-UHFFFAOYSA-N 0.000 description 1
• JOZZAIIGWFLONA-UHFFFAOYSA-N 3-methylbutan-2-amine Chemical compound CC(C)C(C)N JOZZAIIGWFLONA-UHFFFAOYSA-N 0.000 description 1
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
• XIDCXQTZWYQGJQ-UHFFFAOYSA-N 4-(2-chloropyridin-4-yl)-2-(2,5-diazabicyclo[2.2.1]heptan-2-yl)-1,3-thiazole Chemical compound C1=NC(Cl)=CC(C=2N=C(SC=2)N2C3CC(NC3)C2)=C1 XIDCXQTZWYQGJQ-UHFFFAOYSA-N 0.000 description 1
• ATVUYSCEYHQUQX-UHFFFAOYSA-N 4-(2-chloropyridin-4-yl)-6-methyl-2-methylsulfanylpyrimidine Chemical compound CSC1=NC(C)=CC(C=2C=C(Cl)N=CC=2)=N1 ATVUYSCEYHQUQX-UHFFFAOYSA-N 0.000 description 1
• VLEGEAGQPWYQDQ-UHFFFAOYSA-N 4-(3-chloroindazol-1-yl)-n-(1-phenylethyl)pyridin-2-amine Chemical compound C=1C(N2C3=CC=CC=C3C(Cl)=N2)=CC=NC=1NC(C)C1=CC=CC=C1 VLEGEAGQPWYQDQ-UHFFFAOYSA-N 0.000 description 1
• VLEGEAGQPWYQDQ-AWEZNQCLSA-N 4-(3-chloroindazol-1-yl)-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@@H](NC=2N=CC=C(C=2)N2C3=CC=CC=C3C(Cl)=N2)C)=CC=CC=C1 VLEGEAGQPWYQDQ-AWEZNQCLSA-N 0.000 description 1
• BPVKLTMPFYRYCP-DZIBYMRMSA-N 4-[2-(2,5-diazabicyclo[2.2.1]heptan-2-yl)-6-methylpyrimidin-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@@H](NC=2N=CC=C(C=2)C=2N=C(N=C(C)C=2)N2C3CC(NC3)C2)C)=CC=CC=C1 BPVKLTMPFYRYCP-DZIBYMRMSA-N 0.000 description 1
• KNKZWNBDGQAYTQ-WBAXXEDZSA-N 4-[2-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,3-thiazol-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(SC=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 KNKZWNBDGQAYTQ-WBAXXEDZSA-N 0.000 description 1
• TWYYQCKDAVLTKR-UHFFFAOYSA-N 4-[3-(2,5-diazabicyclo[2.2.1]heptan-2-yl)indazol-1-yl]-n-(1-phenylethyl)pyridin-2-amine Chemical compound C=1C(N2C3=CC=CC=C3C(N3C4CC(NC4)C3)=N2)=CC=NC=1NC(C)C1=CC=CC=C1 TWYYQCKDAVLTKR-UHFFFAOYSA-N 0.000 description 1
• TWYYQCKDAVLTKR-LMBAYHJBSA-N 4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]indazol-1-yl]-n-(1-phenylethyl)pyridin-2-amine Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(C1=CC=CC=C11)=NN1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 TWYYQCKDAVLTKR-LMBAYHJBSA-N 0.000 description 1
• PKWBFXMNHSZDTB-SJQFFEKCSA-N 4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]indazol-1-yl]-n-[1-(2-fluorophenyl)ethyl]pyridin-2-amine Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(C1=CC=CC=C11)=NN1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1F PKWBFXMNHSZDTB-SJQFFEKCSA-N 0.000 description 1
• FDAUXZFXTPDSRM-XTWGIRIWSA-N 4-[4-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)quinazolin-2-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@@H](NC=2N=CC=C(C=2)C=2N=C3C=CC=CC3=C(N3C4CC(N(C4)C)C3)N=2)C)=CC=CC=C1 FDAUXZFXTPDSRM-XTWGIRIWSA-N 0.000 description 1
• UXAGYDYQHFDNBY-VRJTXETASA-N 4-[4-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]quinolin-2-yl]-n-(1-phenylethyl)pyridin-2-amine Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(C1=CC=CC=C1N=1)=CC=1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 UXAGYDYQHFDNBY-VRJTXETASA-N 0.000 description 1
• CXOMHPRMHWPDIM-SNRMKQJTSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3N=CN=C3C=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 CXOMHPRMHWPDIM-SNRMKQJTSA-N 0.000 description 1
• JKVGSSMZDIFZSF-RFFXKOPCSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-(1-phenylethyl)pyridin-2-amine Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 JKVGSSMZDIFZSF-RFFXKOPCSA-N 0.000 description 1
• AXBBTYGYYOURMC-HGVHAKBWSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-(3-methylbutan-2-yl)pyridin-2-amine Chemical compound C([C@]1(NC[C@]2([H])C1)[H])N2C(N1C=CN=C1C=1)=NC=1C1=CC=NC(NC(C)C(C)C)=C1 AXBBTYGYYOURMC-HGVHAKBWSA-N 0.000 description 1
• PBCNPJLVYGBQFI-VXKWHMMOSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-(naphthalen-1-ylmethyl)pyridin-2-amine Chemical compound C1=CC=C2C(CNC=3N=CC=C(C=3)C=3N=C(N4C=CN=C4C=3)N3C[C@]4(NC[C@]3([H])C4)[H])=CC=CC2=C1 PBCNPJLVYGBQFI-VXKWHMMOSA-N 0.000 description 1
• JKVGSSMZDIFZSF-VDGAXYAQSA-N 4-[5-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(NC[C@]2([H])C3)[H])=CC=CC=C1 JKVGSSMZDIFZSF-VDGAXYAQSA-N 0.000 description 1
• QVTDUABYWRUBET-VRJTXETASA-N 4-[5-[(1s,4s)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-(1-phenylethyl)pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)CC)[H])N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 QVTDUABYWRUBET-VRJTXETASA-N 0.000 description 1
• QVTDUABYWRUBET-NYVOZVTQSA-N 4-[5-[(1s,4s)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)CC)[H])=CC=CC=C1 QVTDUABYWRUBET-NYVOZVTQSA-N 0.000 description 1
• XHQNKBJBTQDUFF-UHFFFAOYSA-N 4-[5-[5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidin-7-yl]-n-(1-phenylethyl)-3h-pyridin-4-amine Chemical compound C=1C=CC=CC=1C(C)NC1(C=2N=C(N3C=CN=C3C=2)N2C3CC(N(C3)CC(F)F)C2)CC=NC=C1 XHQNKBJBTQDUFF-UHFFFAOYSA-N 0.000 description 1
• KJOIOBIBHCDHSZ-BVVFMGSASA-N 4-[6-methyl-2-(2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl)pyrimidin-4-yl]-n-[(1s)-1-phenylethyl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2C=C(C)N=C(N=2)N2CC3CC2CN3C(C)C)=CC=CC=C1 KJOIOBIBHCDHSZ-BVVFMGSASA-N 0.000 description 1
• NQTVSPWQETZNLU-UHFFFAOYSA-N 4-chloro-2-(2-chloropyridin-4-yl)quinoline Chemical compound C1=NC(Cl)=CC(C=2N=C3C=CC=CC3=C(Cl)C=2)=C1 NQTVSPWQETZNLU-UHFFFAOYSA-N 0.000 description 1
• ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
• ZNOOPTUPFYDTSW-UHFFFAOYSA-N 7-(2-chloropyridin-4-yl)-5-[5-(2,2-difluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]imidazo[1,2-c]pyrimidine Chemical compound FC(F)CN1CC2CC1CN2C(N1C=CN=C1C=1)=NC=1C1=CC=NC(Cl)=C1 ZNOOPTUPFYDTSW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• YCKUKVNHCSJVMB-UHFFFAOYSA-N C(c1ccccc1)Nc1nccc(-[n](c2c3cccc2)nc3N2C(C3)CNC3C2)c1 Chemical compound C(c1ccccc1)Nc1nccc(-[n](c2c3cccc2)nc3N2C(C3)CNC3C2)c1 YCKUKVNHCSJVMB-UHFFFAOYSA-N 0.000 description 1
• PUGFZQLLSBNMEZ-UHFFFAOYSA-N CC(C)(C)OC(N1C(CNc2nc(-c3cc(Cl)ncc3)nc3c2cccc3)C(C2)C2C1)=O Chemical compound CC(C)(C)OC(N1C(CNc2nc(-c3cc(Cl)ncc3)nc3c2cccc3)C(C2)C2C1)=O PUGFZQLLSBNMEZ-UHFFFAOYSA-N 0.000 description 1
• MDJGFQFXGRBWGL-UHFFFAOYSA-N CC(C)(C)OC(N1C(CNc2nc(Cl)nc3c2cccc3)C(C2)C2C1)=O Chemical compound CC(C)(C)OC(N1C(CNc2nc(Cl)nc3c2cccc3)C(C2)C2C1)=O MDJGFQFXGRBWGL-UHFFFAOYSA-N 0.000 description 1
• AWAZGPBUVSVEEK-XOYNAWAESA-N CC(C)N(CC1C2)C2CN1c1nc(-c2cc(N[C@@H](C)c3c(cccc4)c4ccc3)ncc2)cc2ncn[n]12 Chemical compound CC(C)N(CC1C2)C2CN1c1nc(-c2cc(N[C@@H](C)c3c(cccc4)c4ccc3)ncc2)cc2ncn[n]12 AWAZGPBUVSVEEK-XOYNAWAESA-N 0.000 description 1
• LWQDICDZDSPXPQ-XOYNAWAESA-N CC(C)N(CC1C2)C2CN1c1nc(-c2cc(N[C@@H](C)c3ccccc3)ncc2)nc2c1cccc2 Chemical compound CC(C)N(CC1C2)C2CN1c1nc(-c2cc(N[C@@H](C)c3ccccc3)ncc2)nc2c1cccc2 LWQDICDZDSPXPQ-XOYNAWAESA-N 0.000 description 1
• BYCQTSBDFUNCCD-HHYXZILKSA-N CCCCN(CC1C2)C2CN1C([n]1c(C2C)ncc1)=NC2c1cc(N[C@@H](C)c2ccccc2)ncc1 Chemical compound CCCCN(CC1C2)C2CN1C([n]1c(C2C)ncc1)=NC2c1cc(N[C@@H](C)c2ccccc2)ncc1 BYCQTSBDFUNCCD-HHYXZILKSA-N 0.000 description 1
• LRXQHKLZEBCTDL-RPCJCACASA-N C[C@@H](c1cccc2c1cccc2)Nc1nccc(-c2cc3ncn[n]3c([N-]3C(C4)CNC4C3)n2)c1 Chemical compound C[C@@H](c1cccc2c1cccc2)Nc1nccc(-c2cc3ncn[n]3c([N-]3C(C4)CNC4C3)n2)c1 LRXQHKLZEBCTDL-RPCJCACASA-N 0.000 description 1
• BBLOJEWCGIQPDH-IVINKASTSA-N C[C@@H](c1ccccc1)Nc1nccc(-c2cc3ncc[n]3c(N3C(C4)CN(CCOc5ccccc5)C4C3)n2)c1 Chemical compound C[C@@H](c1ccccc1)Nc1nccc(-c2cc3ncc[n]3c(N3C(C4)CN(CCOc5ccccc5)C4C3)n2)c1 BBLOJEWCGIQPDH-IVINKASTSA-N 0.000 description 1
• QGKQXIRIUYZUDY-CCGQDMKZSA-N C[C@@H](c1ccccc1)Nc1nccc(-c2cc3ncc[n]3c(N3C(C4)CN(Cc5ccccc5)C4C3)n2)c1 Chemical compound C[C@@H](c1ccccc1)Nc1nccc(-c2cc3ncc[n]3c(N3C(C4)CN(Cc5ccccc5)C4C3)n2)c1 QGKQXIRIUYZUDY-CCGQDMKZSA-N 0.000 description 1
• VZMQHTHDLXOOET-RPCJCACASA-N C[C@@H](c1ccccc1)Nc1nccc(-c2nc(cccc3)c3c(N3C(C4)CNC4C3)n2)c1 Chemical compound C[C@@H](c1ccccc1)Nc1nccc(-c2nc(cccc3)c3c(N3C(C4)CNC4C3)n2)c1 VZMQHTHDLXOOET-RPCJCACASA-N 0.000 description 1
• 102000004631 Calcineurin Human genes 0.000 description 1
• 108010042955 Calcineurin Proteins 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• JYYNAJVZFGKDEQ-UHFFFAOYSA-N Cc1ccnc(C)c1 Chemical compound Cc1ccnc(C)c1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 102100030013 Endoribonuclease Human genes 0.000 description 1
• 101710199605 Endoribonuclease Proteins 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 206010017711 Gangrene Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 229940123866 Protein kinase C beta inhibitor Drugs 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
• 241000159243 Toxicodendron radicans Species 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• MUUXBTFQEXVEEI-UHFFFAOYSA-N [2-(dimethyl-$l^{3}-silanyl)phenyl]-dimethylsilicon Chemical compound C[Si](C)C1=CC=CC=C1[Si](C)C MUUXBTFQEXVEEI-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000010398 acute inflammatory response Effects 0.000 description 1
• 125000004442 acylamino group Chemical group 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 101150045355 akt1 gene Proteins 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 238000011316 allogeneic transplantation Methods 0.000 description 1
• 108010004469 allophycocyanin Proteins 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 150000001414 amino alcohols Chemical class 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000005911 anti-cytotoxic effect Effects 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 239000000305 astragalus gummifer gum Substances 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 201000004995 autoimmune glomerulonephritis Diseases 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• FHCIILYMWWRNIZ-UHFFFAOYSA-N benzhydryl(chloro)silane Chemical compound C=1C=CC=CC=1C([SiH2]Cl)C1=CC=CC=C1 FHCIILYMWWRNIZ-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 125000006267 biphenyl group Chemical group 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• BTWHOYYUFRKLCO-UHFFFAOYSA-N butyl-(2-tert-butylphenyl)-chloro-phenylsilane Chemical compound C(C)(C)(C)C1=C(C=CC=C1)[Si](Cl)(C1=CC=CC=C1)CCCC BTWHOYYUFRKLCO-UHFFFAOYSA-N 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• KWYZNESIGBQHJK-UHFFFAOYSA-N chloro-dimethyl-phenylsilane Chemical compound C[Si](C)(Cl)C1=CC=CC=C1 KWYZNESIGBQHJK-UHFFFAOYSA-N 0.000 description 1
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 238000003568 cytokine secretion assay Methods 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000007872 degassing Methods 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• IIJNMGXVEGFXRQ-UHFFFAOYSA-N ethyl 3-(2-chloropyridin-4-yl)-3-oxopropanoate;lithium Chemical compound [Li].CCOC(=O)CC(=O)C1=CC=NC(Cl)=C1 IIJNMGXVEGFXRQ-UHFFFAOYSA-N 0.000 description 1
• VNSAFDGQUZWUFE-UHFFFAOYSA-N ethyl 3-chloropyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1Cl VNSAFDGQUZWUFE-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000009650 gentamicin protection assay Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
• 150000004820 halides Chemical group 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical class Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Chemical group O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 150000003949 imides Chemical group 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• XLTUPERVRFLGLJ-UHFFFAOYSA-N isothiocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=S XLTUPERVRFLGLJ-UHFFFAOYSA-N 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 150000002611 lead compounds Chemical class 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
• CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 229940098895 maleic acid Drugs 0.000 description 1
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910000000 metal hydroxide Inorganic materials 0.000 description 1
• 150000004692 metal hydroxides Chemical class 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• NNBBQNFHCVVQHZ-UHFFFAOYSA-N methyl carbamimidothioate;sulfuric acid Chemical compound CSC(N)=N.OS(O)(=O)=O NNBBQNFHCVVQHZ-UHFFFAOYSA-N 0.000 description 1
• 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
• 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• ATQRNTSLYSZOSI-MXQSGTKOSA-N n-(1-phenylethyl)-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C(C)C)[H])N2C(N1C=CN=C1C=1)=NC=1C(C=1)=CC=NC=1NC(C)C1=CC=CC=C1 ATQRNTSLYSZOSI-MXQSGTKOSA-N 0.000 description 1
• MQPYJDLLBABSOY-UHFFFAOYSA-N n-(2-carbamoylphenyl)-2-chloropyridine-4-carboxamide Chemical compound NC(=O)C1=CC=CC=C1NC(=O)C1=CC=NC(Cl)=C1 MQPYJDLLBABSOY-UHFFFAOYSA-N 0.000 description 1
• HHOLHUJDDAONTA-MFUMQWNRSA-N n-(3-methylbutan-2-yl)-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C(C)C)[H])N2C(N1C=CN=C1C=1)=NC=1C1=CC=NC(NC(C)C(C)C)=C1 HHOLHUJDDAONTA-MFUMQWNRSA-N 0.000 description 1
• ATQRNTSLYSZOSI-VJBMBRPKSA-N n-[(1s)-1-phenylethyl]-4-[5-[(1s,4s)-2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl]imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C1([C@H](C)NC=2N=CC=C(C=2)C=2N=C(N3C=CN=C3C=2)N2C[C@]3(N(C[C@]2([H])C3)C(C)C)[H])=CC=CC=C1 ATQRNTSLYSZOSI-VJBMBRPKSA-N 0.000 description 1
• REGNSKDFHUYCSB-UHFFFAOYSA-N n-[2-[tert-butyl(diphenyl)silyl]oxyethyl]-6-(2-chloropyridin-4-yl)-2-(2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl)pyrimidin-4-amine Chemical compound CC(C)N1CC2CC1CN2C(N=C(C=1)C=2C=C(Cl)N=CC=2)=NC=1NCCO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 REGNSKDFHUYCSB-UHFFFAOYSA-N 0.000 description 1
• HPBZIFNOQIRMFT-UHFFFAOYSA-N n-[2-[tert-butyl(diphenyl)silyl]oxyethyl]-6-(2-chloropyridin-4-yl)-2-methylsulfanylpyrimidin-4-amine Chemical compound C=1C(C=2C=C(Cl)N=CC=2)=NC(SC)=NC=1NCCO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 HPBZIFNOQIRMFT-UHFFFAOYSA-N 0.000 description 1
• QSZPEWUJLWEIIW-UHFFFAOYSA-N n-[2-[tert-butyl(diphenyl)silyl]oxyethyl]-6-[2-(1-phenylethylamino)pyridin-4-yl]-2-(2-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-5-yl)pyrimidin-4-amine Chemical compound CC(C)N1CC2CC1CN2C(N=C(C=1)C=2C=C(NC(C)C=3C=CC=CC=3)N=CC=2)=NC=1NCCO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 QSZPEWUJLWEIIW-UHFFFAOYSA-N 0.000 description 1
• YCKUKVNHCSJVMB-ICSRJNTNSA-N n-benzyl-4-[3-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]indazol-1-yl]pyridin-2-amine Chemical class C([C@]1(NC[C@]2([H])C1)[H])N2C(C1=CC=CC=C11)=NN1C(C=1)=CC=NC=1NCC1=CC=CC=C1 YCKUKVNHCSJVMB-ICSRJNTNSA-N 0.000 description 1
• VPWLVRVJXPFKLF-UHFFFAOYSA-N n-benzyl-4-[5-(2,5-diazabicyclo[2.2.1]heptan-2-yl)imidazo[1,2-c]pyrimidin-7-yl]pyridin-2-amine Chemical compound C=1C(C=2N=C(N3C=CN=C3C=2)N2C3CC(NC3)C2)=CC=NC=1NCC1=CC=CC=C1 VPWLVRVJXPFKLF-UHFFFAOYSA-N 0.000 description 1
• RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
• 230000007896 negative regulation of T cell activation Effects 0.000 description 1
• 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• XURVRZSODRHRNK-UHFFFAOYSA-N o-quinodimethane Chemical compound C=C1C=CC=CC1=C XURVRZSODRHRNK-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
• 125000005545 phthalimidyl group Chemical group 0.000 description 1
• 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 230000010118 platelet activation Effects 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 230000001185 psoriatic effect Effects 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• LDFKYHHSSGRMPD-UHFFFAOYSA-M sodium 2-(2-chloropyridin-4-yl)-3H-quinazolin-4-one hydroxide Chemical compound [OH-].[Na+].ClC1=NC=CC(=C1)C1=NC2=CC=CC=C2C(N1)=O LDFKYHHSSGRMPD-UHFFFAOYSA-M 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• ZVWLQTDCMAGVKX-RYUDHWBXSA-N tert-butyl (1s,4s)-5-(2-chloroquinazolin-4-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1=CC=C2C(N3C[C@]4(N(C[C@]3([H])C4)C(=O)OC(C)(C)C)[H])=NC(Cl)=NC2=C1 ZVWLQTDCMAGVKX-RYUDHWBXSA-N 0.000 description 1
• BGVCQJKTMDNEAB-HOTGVXAUSA-N tert-butyl (1s,4s)-5-[2-(2-chloropyridin-4-yl)quinazolin-4-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)OC(C)(C)C)[H])N2C(C1=CC=CC=C1N=1)=NC=1C1=CC=NC(Cl)=C1 BGVCQJKTMDNEAB-HOTGVXAUSA-N 0.000 description 1
• WVSJVAUBSKOKKB-XWDHDVEBSA-N tert-butyl (2S,4R)-4-[tert-butyl(diphenyl)silyl]-2-hydroxy-2-(1-hydroxyethyl)pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@](C[C@H](C1)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)(C(C)O)O WVSJVAUBSKOKKB-XWDHDVEBSA-N 0.000 description 1
• UFJNFQNQLMGUTQ-JGVFFNPUSA-N tert-butyl (2s,4r)-4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1CO UFJNFQNQLMGUTQ-JGVFFNPUSA-N 0.000 description 1
• HHHWEVOSBOJPHE-UHFFFAOYSA-N tert-butyl 5-[4-(2-chloropyridin-4-yl)-1,3-thiazol-2-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2CC1CN2C(SC=1)=NC=1C1=CC=NC(Cl)=C1 HHHWEVOSBOJPHE-UHFFFAOYSA-N 0.000 description 1
• MHZMQQLFQMCWPS-BVVFMGSASA-N tert-butyl 5-[4-methyl-6-[2-[[(1s)-1-phenylethyl]amino]pyridin-4-yl]pyrimidin-2-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1([C@@H](NC=2N=CC=C(C=2)C=2N=C(N=C(C)C=2)N2C3CC(N(C3)C(=O)OC(C)(C)C)C2)C)=CC=CC=C1 MHZMQQLFQMCWPS-BVVFMGSASA-N 0.000 description 1
• GJHFUWZBTZJSCZ-UHFFFAOYSA-N tert-butyl 5-[7-[2-(3-methylbutan-2-ylamino)pyridin-4-yl]imidazo[1,2-c]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1=NC(NC(C)C(C)C)=CC(C=2N=C(N3C=CN=C3C=2)N2C3CC(N(C3)C(=O)OC(C)(C)C)C2)=C1 GJHFUWZBTZJSCZ-UHFFFAOYSA-N 0.000 description 1
• JEATYNJIXFUTEK-UHFFFAOYSA-N tert-butyl 5-[7-[2-(naphthalen-1-ylmethylamino)pyridin-4-yl]imidazo[1,2-c]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1=CC=C2C(CNC=3N=CC=C(C=3)C=3N=C(N4C=CN=C4C=3)N3CC4CC3CN4C(=O)OC(C)(C)C)=CC=CC2=C1 JEATYNJIXFUTEK-UHFFFAOYSA-N 0.000 description 1
• PSZLQCYJFCYNPV-UHFFFAOYSA-N tert-butyl 5-carbamothioyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1N(C(N)=S)C2 PSZLQCYJFCYNPV-UHFFFAOYSA-N 0.000 description 1
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
• QFNFDHNZVTWZED-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrazol-1-ylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NC(=O)OC(C)(C)C)N1C=CC=N1 QFNFDHNZVTWZED-UHFFFAOYSA-N 0.000 description 1
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• QHOKENWFMZXSEU-UHFFFAOYSA-N tetrabutylazanium;nitrate Chemical compound [O-][N+]([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC QHOKENWFMZXSEU-UHFFFAOYSA-N 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 230000009424 thromboembolic effect Effects 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
• PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
• HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1